• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • LIVE NOW
        Title
        User
        • Sign In
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5637
    • Acute Myelogenous Leukemia 149
    • Bladder Cancer 49
    • Bone Metastases 1
    • Brain Cancer 16
    • Breast Cancer 121
    • Business Management 2
    • Cervical Cancer 2
    • Chronic Lymphocytic Leukemia 157
    • Chronic Myelogenous Leukemia 21
    • Colorectal Cancer 75
    • Gastrointestinal Cancer 70
    • General 246
    • Head and Neck Cancers 34
    • Hematologic Malignancies 79
    • Hodgkin Lymphoma 18
    • Immunotherapy 88
    • Kidney Cancer 364
    • Liver Cancer 11
    • Lymphoma 145
    • Melanoma and Skin Cancer 51
    • Multiple Myeloma 339
    • Myeloproliferative Disease 15
    • News 115
    • Non-Hodgkin Lymphoma 47
    • Non-Small Cell Lung Cancer 267
    • Other 111
    • Ovarian Cancer 10
    • Pancreatic Cancer 54
    • Patient Resources 27
    • Prostate Cancer 148
    • Small Cell Lung Cancer 58
    • Soft Tissue Sarcoma 9
    • Supportive Care 38
    • Testicular Cancer 2
    • Urology 6
    • Uterine Cancer 2

    • About
    • Contact
    University of Virginia Health Center

    UVA Cancer Center

    My videos
    Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward
    0:02:04

    Investigational Melanoma Vaccine, Seviprotimut-L: Moving Forward

    Craig Slingluff, MD of @UVACancerCenter answers the study design and what is next for phase III data for a melanoma vaccine, seviprotimut-L.

    _____________

    -- MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients --

    Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int'l., (Holdings) Inc., is presenting clinical data from MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), its ongoing Phase III clinical study of seviprotimut-L, an investigational melanoma vaccine candidate, on November 8 at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland.

    MAVIS is an adaptive phase III multicenter, double-blind, placebo-controlled trial to assess the safety and efficacy of seviprotimut-L, with primary endpoints of recurrence-free survival (RFS) and overall survival (OS) in patients with American Joint Cancer Committee (AJCC) Stage IIB / C, IIIA, IIIB / C melanoma at high risk of recurrence following definitive surgical resection.

    Highlights of the data presented include:

    • Improved outcomes in Stage IIB/C patients: Interim analysis of subgroups suggested enhanced RFS for seviprotimut-L among those with AJCC stage IIB/IIC melanoma, as well as those under age 60.
    • Favorable adverse event profile: Seviprotimut-L was well-tolerated with treatment-emergent adverse events (AEs) similar to patients given placebo.

    Treatment of Stage IIB/IIC melanoma is primarily limited to surgery, coupled with a "wait and see" approach. However, recurrence of the disease can occur following definitive resection of the melanoma. Many patients progress to more advanced stages following resection and 5-year survival rates fall sharply after a patient passes from localized Stage II melanoma into regional Stage III disease (98.4% to 63.6%). Five-year survival rates are distinctly lower (22.4%) for metastatic Stage IV.1

    Read here: https://www.oncologytube.com/video/annual-meeting-of-the-society-for-immunotherapy-of-cancer-sitc-2019-polynoma-presenting-interim-phase-iii-evidence-for-its-investigational-melanoma-vaccine-seviprotimut-l

    Melanoma and Skin Cancer
    2 Views
    3 weeks ago
    UVA Cancer Center
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter
    0:04:12

    Phase III Data for Investigational Melanoma Vaccine, Seviprotimut-L #SITC @UVACancerCenter

    Melanoma and Skin Cancer
    23 Views
    3 weeks ago
    UVA Cancer Center
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

      Copyright 2019 Medicus Networks, Inc.